Sasanka M. Handunnetti

Author

The University of Melbourne ORCID

Also Known As

S.M. Handunnetti, Sasanka Handunnetti, Sasanka M Handunnetti, Sasanka M. Handunnetti, Shiroma M. Handunnetti

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

The University of Melbourne Peter MacCallum Cancer Centre Walter and Eliza Hall Institute of Medical Research The Royal Melbourne Hospital St Vincent's Hospital Melbourne

About

Sasanka M. Handunnetti is an author at The University of Melbourne specializing in medicine, immunology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	282
2	Immunology	5	5	282
3	Cell Biology	2	2	84
4	Engineering	1	1	27
5	Orthopaedics	1	1	38

Sasanka M. Handunnetti

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma Constantine S. Tam, Mary Ann Anderson, Christiane Pott, New England Journal of Medicine	2018	417
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance Piers Blombery, Ella R. Thompson, Thomas E. Lew, Blood Advances Hematological MalignancyBtk Leu528trp MutationOncologyMedicineMixed-phenotype Acute Leukemia	2022	89
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax Victor S. Lin, Thomas E. Lew, Sasanka M. Handunnetti, Blood	2020	84
Clonal hematopoiesis, myeloid disorders and <i>BAX</i>-mutated myelopoiesis in patients receiving venetoclax for CLL Piers Blombery, Thomas E. Lew, Michael A. Dengler, Blood Hematological MalignancySimultaneous Bcl2 MutationsOncologyAcute Myeloid LeukemiaMalignant Blood Disorder	2021	71
Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial Anthony R. Mato, Lindsey E. Roeker, John N. Allan, American Journal of Hematology	2018	70
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition Thomas E. Lew, Victor S. Lin, Edward R. Scheffer Cliff, Blood Advances	2021	70
BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib Sasanka M. Handunnetti, Chloe Pek Sang Tang, Tamia Nguyen, Blood	2019	65
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans Gasim Dobie, Fahd A. Kuriri, Musab M. A. Omar, Blood Advances Tyrosine KinaseImmunologyPharmacotherapyIntegrin αIibβ3Hematological Malignancy	2019	57
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Blood Advances Attainment PlateausMixed-phenotype Acute LeukemiaImmunologyPathologyPharmacotherapy	2020	38
Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study Sasanka M. Handunnetti, Mary Ann Anderson, Kate Burbury, Blood	2019	32

Page 1